
Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.

Your AI-Trained Oncology Knowledge Connection!


Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.

Expert perspectives on optimal genomic testing practices in patients with prostate cancer.

Discussion on the selection of therapy for a patient with metastatic HSPC in the context of available agents and FDA approvals.

Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.

A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.

A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

Published: April 6th 2022 | Updated:

Published: April 13th 2022 | Updated:

Published: April 20th 2022 | Updated:

Published: April 27th 2022 | Updated:

Published: April 13th 2022 | Updated:

Published: April 20th 2022 | Updated: